Harry Zhabilov
Glendale, CA (USA)
Role(s):
Founder/Owner/Principal
Immunotech Laboratories,Inc
Find More Startups
Startup
Location:
Glendale
Industry:
Bio-Technology
Year Founded:
2007
Number Employees:
1-10 people
Description:
Immunotech Laboratories Inc. is an organization with full indefinite licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment of the HIV/AIDS indication. IPF is a peptide molecule that has a strong affinity to bind with the HIV virus’ peptide components identified as gp41 and gp120 antigens, rendering them as super antigens, and taking away from them their stealthiness and their capability to destroy the immune system. In addition to this mechanism of action, IPF will also enhance and upgrade the immune system components and criteria, as such resulting in a double impact approach of both behaving as a novel fusion treatment as well as an immuno-modulator.
Immunotech Laboratories Inc. will employ several strategies of market penetration, by initially introducing its product as a complimentary treatment along with an Anti Retro Viral partner Pharmaceutical company with established manufacturing and distribution capabilities, securing a position in the global HAART market. This will eventuall lead our product to take on a more significant dominant role in the ARV resistant segment of the HIV/AIDS population. The result of which will be further market penetration and increased market share.
Both co founders, Harry Zhabilov Jr. and Ara Antoine Ghanime bring to the organization decades of scientific research, and both regulatory and compliance know how and experience. They share between them and Immunotech’s management team, an average of more then twenty years of experience, and exposure to a whole spectrum of organizations in the pharmaceutical, biotech and medical device industries.
Immunotech Laboratories Inc. will be an organization with its core competency established in developing new novel therapeutic molecules for the treatment of HIV/AIDS and subsequently in developing a Preventive HIV Vaccine and follow up booster shots. The potential of immuno-modulators within the global market of existing treatments is strong and solid, unfortunately driven by the ongoing mutation of ARV resistant viral strains, ongoing compliance issues, toxicity and quality of life barriers and not to say the least a prohibitive cost burden on both the micro and macro levels.
Immunotech Laboratories Inc. is basing its forward drive on decades of research and development in the field of immunomodulators. We believe that tremendous strides have to date been made by Harry Zhabilov Jr. in identifying critical active elements specifically IPF, the subject of a patent application published in 2006. We also believe that the stage is set to take the effort into the next level. In order to accomplish this, we have, based on our industry and regulatory experience estimated a required capital of 20 million. This by itself is attractive to the investment community given current prohibitive financial investment requirements needed to take a similar product from concept to commercialization. We also believe that the recovery of initial capital investment and return on investment will be accomplished within the first 3 years of operation and royalty fees collected over the life of the patent based on market share provide a sound element for the investment community.
Immunotech Laboratories Inc. in contrast to other biotech start ups is solidly based on a proven technological foundation and has scientifically demonstrated that its novel immunomodulator molecule IPF for the treatment of HIV/AIDS is a viable alternative and complimentary treatment product. Furthermore Immunotech has taken substantial experimental strides in preparing the framework for its next product in the pipeline in the development of a Preventive AIDS Vaccine. We take pride in this work, and believe that our sound scientific platform provides the foundation to create wealth while alleviating a tremendous economic burden and pain from humanity.